From: Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
Costs, € | Additional costs versus Aptima, € | |
---|---|---|
Aptima® HPV | 11,809,879.39 € | – |
Hybrid Capture® 2 | 393,371,446.36 €* | 381,561,664.97 € |
Cobas® 4800 | 14,611,150.11 € | 2,891,270.72 € |